MediXall (MDXL) EPS (Weighted Average and Diluted) (2021 - 2024)
MediXall's EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at $0.0 for Q3 2024.
- For Q3 2024, EPS (Weighted Average and Diluted) rose 115.93% year-over-year to $0.0; the TTM value through Sep 2024 reached -$0.01, up 75.0%, while the annual FY2023 figure was -$0.04, 33.33% up from the prior year.
- EPS (Weighted Average and Diluted) reached $0.0 in Q3 2024 per MDXL's latest filing, up from -$0.0 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.0 in Q3 2024 to a low of -$0.02 in Q2 2021.
- Average EPS (Weighted Average and Diluted) over 4 years is -$0.01, with a median of -$0.01 recorded in 2021.
- Peak YoY movement for EPS (Weighted Average and Diluted): dropped 0.0% in 2023, then soared 115.93% in 2024.
- A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.02 in 2021, then skyrocketed by 43.76% to -$0.01 in 2022, then dropped by 0.0% to -$0.01 in 2023, then skyrocketed by 115.93% to $0.0 in 2024.
- Per Business Quant, the three most recent readings for MDXL's EPS (Weighted Average and Diluted) are $0.0 (Q3 2024), -$0.0 (Q2 2024), and -$0.0 (Q1 2024).